Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle

被引:47
作者
Gajiwala, Snehal [1 ]
Torgeson, Anna [2 ]
Garrido-Laguna, Ignacio [3 ]
Kinsey, Conan [3 ]
Lloyd, Shane [2 ]
机构
[1] Univ Utah, Sch Med, Salt Lake City, UT USA
[2] Univ Utah, Sch Med, Huntsman Canc Inst, Dept Radiat Oncol, Salt Lake City, UT USA
[3] Univ Utah, Dept Internal Med, Huntsman Canc Inst, Sch Med, Salt Lake City, UT USA
关键词
Radiation therapy (RT); immunotherapy; pancreas cancer; tumor microenvironment (TME); vaccine; STAGE-III MELANOMA; T-CELL; LOCAL RADIOTHERAPY; ABSCOPAL; CHEMOTHERAPY; INHIBITION; IPILIMUMAB; PHENOTYPE; SURVIVAL; TUMORS;
D O I
10.21037/jgo.2018.05.16
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, with its mortality rate approaching its incidence rate every year. Accordingly, much interest has been generated in harnessing the immune system in order to improve survival outcomes for these patients. Pancreatic cancer is not thought to be as immunogenic as other cancers that have seen promising results with immune checkpoint inhibitors alone, therefore likely several targets within the cancer-immunity cycle will need to be employed for successful treatment. We sought to investigate both the current state of the field in immunotherapy in PDAC with a special emphasis on combined approaches with radiation therapy (RT). We also summarized ongoing clinical trials that are examining the use of radiotherapy with other immune-stimulating agents in the treatment of PDAC. A PubMed and clinicaltrials. gov search was conducted using the following search terms, either alone or in combination: "pancreatic cancer", "immunotherapy", and "abscopal effect". Open clinical trials were reviewed and included if they involved both RT and other immune-stimulating agents. Pancreatic cancers tend to reside within immune-suppressive tumor microenvironments (TME), express PD-L1, and secrete several immuno-suppressive agents, such as TGF-B, IL-10, indoleamine 2,3-dioxygenase, galectin-1. Whole-cell vaccine therapies, peptide and protein vaccines, dendritic cell vaccines, and vaccines with microorganisms have been investigated by themselves with promising results. Open clinical trials are currently investigating the use of these vaccines, which increase antigen presentation, with treatments that stimulate release of tumor antigens including RT. There are currently at least 21 open clinical trials investigating the combination of RT with other immune-stimulating agents. The combination of RT and immunotherapy may be a promising avenue for PDAC treatment and deserves further research.
引用
收藏
页码:1014 / 1026
页数:13
相关论文
共 62 条
[1]  
[Anonymous], 32 SITC ANN M NAT HA
[2]  
[Anonymous], PANCREATIC CANC VACC
[3]  
[Anonymous], J CLIN ONCOL S4S
[4]  
[Anonymous], 2017, NATL COMPREHENSIVE C
[5]  
[Anonymous], ESMO 2017 C SEP 8 12
[6]   Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer [J].
Balachandran, Vinod P. ;
Luksza, Marta ;
Zhao, Julia N. ;
Makarov, Vladimir ;
Moral, John Alec ;
Remark, Romain ;
Herbst, Brian ;
Askan, Gokce ;
Bhanot, Umesh ;
Senbabaoglu, Yasin ;
Wells, Daniel K. ;
Cary, Charles Ian Ormsby ;
Grbovic-Huezo, Olivera ;
Attiyeh, Marc ;
Medina, Benjamin ;
Zhang, Jennifer ;
Loo, Jennifer ;
Saglimbeni, Joseph ;
Abu-Akeel, Mohsen ;
Zappasodi, Roberta ;
Riaz, Nadeem ;
Smoragiewicz, Martin ;
Kelley, Z. Larkin ;
Basturk, Olca ;
Goenen, Mithat ;
Levine, Arnold J. ;
Allen, Peter J. ;
Fearon, Douglas T. ;
Merad, Miriam ;
Gnjatic, Sacha ;
Iacobuzio-Donahue, Christine A. ;
Wolchok, Jedd D. ;
DeMatteo, Ronald P. ;
Chan, Timothy A. ;
Greenbaum, Benjamin D. ;
Merghoub, Taha ;
Leach, Steven D. .
NATURE, 2017, 551 (7681) :512-+
[7]   Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer [J].
Bazhin, Alexandr V. ;
Bayry, Jagadeesh ;
Umansky, Viktor ;
Werner, Jens ;
Karakhanova, Svetlana .
ONCOIMMUNOLOGY, 2013, 2 (09)
[8]   Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients [J].
Bellone, G ;
Turletti, A ;
Artusio, E ;
Mareschi, K ;
Carbone, A ;
Tibaudi, D ;
Robecchi, A ;
Emanuelli, G ;
Rodeck, U .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) :537-547
[9]   CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer [J].
Byrne, Katelyn T. ;
Vonderheide, Robert H. .
CELL REPORTS, 2016, 15 (12) :2719-2732
[10]  
Cohen RB, 2018, AM J CLIN ONCOL